In HER2 + BC harboring PIK3CA-mutation, cell lines and PDX models, MEN1611 acted synergistically when combined with trastuzumab, induced depletion protein, and a pro-inflammatory phenotype [89,90]. This evidence concerns the gene PIK3CA and breast cancer.